The percentages of the predominant autoantibody profiles (more than 10%) in patients with PBC were as follows: AMA and/or AMA-M2 (95.0%), ANA (88.1%), anti-Ro52 (39.5%), anti-gp210 (37.4%), ACA and/or anti-CENP-B (24.4%), anti-sp100 (16.6%), and anti-SSA (14.5%). Here, SP100 is linked to primary biliary cholangitis.